Eli Lilly's retatrutide, a triple-action weight-loss drug, helped people lose an average of 70 pounds over 80 weeks in a major trial. The drug also reduced joint pain and improved sleep problems in people with obesity and related conditions.

• •Retatrutide is described as a triple agonist targeting weight and obesity complications
• •Average weight loss was ~70 pounds over 80 weeks in the trial
• •Trial covered A1C, knee osteoarthritis pain, and obstructive sleep apnea outcomes

Eli Lilly will present new study results on Foundayo (an oral weight-loss and diabetes drug), Mounjaro, and retatrutide at a major diabetes conference. The Foundayo data showed it worked better than two competing pills for type 2 diabetes.

• •Lilly to present data on Foundayo, Mounjaro, and retatrutide at ADA's 86th Scientific Sessions
• •Foundayo data showed it worked better than two competing pills for type 2 diabetes

Eli Lilly's retatrutide, a new weight-loss drug that works three different ways, helped people lose an average of 70 pounds in a big Phase 3 trial. Nearly half of patients lost at least 30% of their body weight, which is as much as people usually lose from weight-loss surgery.

• •Retatrutide is described as a triple agonist in a pivotal Phase 3 obesity trial
• •Average weight loss was approximately 70 pounds in the trial
• •Nearly half of patients lost at least 30% of body weight

• •Patent analysis covers triple-agonist obesity drugs that go beyond GLP-1 mechanisms

• •PatentVest Pulse report covers the triple-agonist obesity drug race
• •Report flags an emerging patent battle in the post-GLP-1 market

Eli Lilly's new obesity drug retatrutide is so effective that people are already making illegal copies of it. The drug hasn't even been fully approved yet, but compounding pharmacies are producing their own versions.

• •Lilly's obesity drug retatrutide is being copied before full approval
• •Compounding pharmacies are making their own versions of the drug

• •Doctors warn against using a fake drug for weight loss
• •Warning involves retatrutide, which is not approved

People are buying retatrutide, Eli Lilly's new weight-loss drug, on the black market because they can't get it through normal channels. The high demand shows how much people want the drug even before it's widely available.

• •Retatrutide is Eli Lilly's experimental GLP weight-loss drug
• •Buyers are sourcing retatrutide on the black market
• •Drug is not yet available through normal channels

• •Retatrutide reportedly hits weight loss levels seen with bariatric surgery

Retatrutide, an experimental weight-loss drug, showed patients lost 28.7% of their body weight in a trial. An intellectual property firm says the real competition next will be over patents as other companies try to develop similar drugs.

• •Retatrutide patients lost 28.7% of their body weight in a trial
• •PatentVest says the next battle will be over intellectual property
• •Other drugmakers are working on similar weight-loss drugs

Boehringer's dual agonist drug (a weight-loss medicine that works in two ways) helped people lose up to 16.6% of their body weight in testing. This is an early result from the company's obesity drug program.

• •Boehringer's dual agonist drug led to up to 16.6% weight loss in a trial
• •The drug works on two targets at once
• •Early-stage result from Boehringer's obesity program

A partner of Gubra is moving a triple-action weight-loss peptide (a drug that works three different ways) into Phase 2 testing (a mid-stage trial to check if it works and is safe). The peptide was originally created by Gubra, a Danish research company.

• •Gubra-originated triple agonist peptide advancing to Phase 2
• •Drug is being developed by an unnamed Gubra partner
• •Targets obesity via three-receptor mechanism

• •Retatrutide is not yet approved
• •It is described as working differently from Ozempic for weight loss

Eli Lilly's retatrutide, a next-generation weight-loss drug, won its first Phase 3 trial (a large test that checks if a drug works in real patients). This is a major step toward getting the drug approved by the FDA.

• •Retatrutide won its first Phase 3 trial
• •Drug is Lilly's next-generation obesity treatment
• •Result is a key step toward FDA approval

• •Gym-goers claim retatrutide is more powerful than Ozempic
• •Article questions whether retatrutide is safe to use

• •Lexaria planning an 18-arm study comparing pills and capsules
• •Test covers two GLP-1 drugs in oral form

• •Local news segment covers retatrutide as a new GLP-class injection

• •GoodRx compares retatrutide and tirzepatide, both Eli Lilly drugs